Breaking News

Quotient Clinical Delivers First In-human Program for Corcept Therapeutics

Focus is on treatment of Cushing’s syndrome and certain cancers

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Quotient Clinical has completed an Enabled-First-in-Human (Enabled-FIH) program for U.S. biotech company Corcept Therapeutics, focusing on a next generation selective glucocorticoid receptor antagonist (CORT125134) in development for the treatment of Cushing’s syndrome and certain cancers. The Enabled-FIH program integrated formulation development, real-time GMP manufacturing and clinical testing, using a single adaptive protocol to assess single and multiple dose safety, pharmacokinetics, and p...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters